{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:57:43Z","timestamp":1760385463829,"version":"3.41.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sumitomo Dainippon"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.bbr.2015.10.044","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:39:08Z","timestamp":1446511148000},"page":"204-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition"],"prefix":"10.1016","volume":"301","author":[{"given":"Masanori","family":"Miyauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichole M.","family":"Neugebauer\u200e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Oyamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-8845","authenticated-orcid":false,"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2015.10.044_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2015.10.044_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cobeha.2015.04.009","article-title":"Pharmacotherapy of cognition in schizophrenia","volume":"4","author":"Meltzer","year":"2015","journal-title":"Curr. Opin. Behav. Sci."},{"key":"10.1016\/j.bbr.2015.10.044_bib0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2015.10.044_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2015.10.044_bib0030","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2015.10.044_bib0035","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1017\/S1461145713000928","article-title":"Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia","volume":"16","author":"Meltzer","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bbr.2009.12.036","article-title":"One-trial object recognition in rats and mice: methodological and theoretical issues","volume":"215","author":"Ennaceur","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2015.10.044_bib0045","doi-asserted-by":"crossref","first-page":"12375","DOI":"10.1073\/pnas.220398097","article-title":"The visual paired-comparison task as a measure of declarative memory","volume":"97","author":"Manns","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbr.2015.10.044_bib0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0070","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jnc.12512","article-title":"Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and DA D2 antagonism and 5-HT1A partial agonism","volume":"128","author":"Huang","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2015.10.044_bib0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hipo.1109","article-title":"Cholinergic system regulation of spatial representation by the hippocampus","volume":"12","author":"Ikonen","year":"2002","journal-title":"Hippocampus"},{"key":"10.1016\/j.bbr.2015.10.044_bib0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.conb.2011.04.006","article-title":"Oscillations and hippocampal-prefrontal synchrony","volume":"21","author":"Colgin","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.neuro.22.1.443","article-title":"Presynaptic ionotropic receptors and the control of transmitter release","volume":"22","author":"MacDermott","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bbr.2015.10.044_bib0090","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s00213-014-3596-0","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens","volume":"231","author":"Huang","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0095","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/00001756-199906030-00028","article-title":"Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain","volume":"10","author":"Guan","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbr.2015.10.044_bib0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF02247425","article-title":"Acute nicotinic blockade produces cognitive impairment in normal humans","volume":"108","author":"Newhouse","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0105","first-page":"145","article-title":"The effects of scopolamine on working memory in healthy young volunteers","volume":"96","author":"Rusted","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0110","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1017\/S1461145712000752","article-title":"The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction","volume":"16","author":"Nathan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","article-title":"Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization","volume":"184","author":"Levin","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0120","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.npp.1300450","article-title":"Effects of nicotine on cognitive deficits in schizophrenia","volume":"29","author":"Harris","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2015.10.044_bib0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.pra.0000442935.15833.c5","article-title":"Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr. Pract."},{"issue":"13","key":"10.1016\/j.bbr.2015.10.044_bib0140","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/npp.2015.176","article-title":"Randomized, double-blind, placebo-controlled study of encenicline, an alpha-7 nicotinic acetylcholine receptor partial agonist as a treatment for cognitive impairment in schizophrenia","volume":"40","author":"Keefe","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00213-011-2357-6","article-title":"Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914\/SEN34625","volume":"218","author":"Marquis","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0166-4328(00)00305-3","article-title":"Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task","volume":"117","author":"Grottick","year":"2000","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2015.10.044_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2013.01.004","article-title":"Activation of the alpha7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT(1) a receptor antagonist","volume":"70","author":"Pandya","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00213-001-0927-8","article-title":"Effects of alpha 4\/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice","volume":"159","author":"Schreiber","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0893-133X(00)00174-3","article-title":"Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats","volume":"24","author":"Jentsch","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0175","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.pharep.2014.02.002","article-title":"A comparison of mecamylamine and bupropion effects on memory-related responses induced by nicotine and scopolamine in the novel object recognition test in mice","volume":"66","author":"Kruk-Slomka","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbr.2015.10.044_bib0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1601-183X.2011.00711.x","article-title":"Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice","volume":"10","author":"Young","year":"2011","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.bbr.2015.10.044_bib0185","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1096\/fj.07-8260com","article-title":"Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment","volume":"21","author":"Zanardi","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.bbr.2015.10.044_bib0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0022-3565(24)36376-1","article-title":"Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes","volume":"280","author":"Chavez-Noriega","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1101\/lm.2274911","article-title":"Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex","volume":"18","author":"Tinsley","year":"2011","journal-title":"Learn. Mem. (Cold Spring Harbor, N.Y.)"},{"key":"10.1016\/j.bbr.2015.10.044_bib0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2004.07.009","article-title":"Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism","volume":"1023","author":"Chung","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2015.10.044_bib0205","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0893-133X(01)00400-6","article-title":"Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat","volume":"26","author":"Shirazi-Southall","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2015.10.044_bib0215","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/npp.2012.64","article-title":"Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist","volume":"37","author":"Horiguchi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0220","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.109.155663","article-title":"Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex","volume":"330","author":"Li","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2015.10.044_bib0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biopsych.2010.08.006","article-title":"Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors","volume":"69","author":"Castner","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2015.10.044_bib0230","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/npp.2008.232","article-title":"Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia","volume":"34","author":"Barak","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2015.10.044_bib0240","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00213-013-3286-3","article-title":"Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia","volume":"231","author":"Roh","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neulet.2010.01.028","article-title":"Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat","volume":"471","author":"Jenkins","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2015.10.044_bib0250","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0269881107067097","article-title":"Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat","volume":"21","author":"Abdul-Monim","year":"2007","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"key":"10.1016\/j.bbr.2015.10.044_bib0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuropharm.2015.04.012","article-title":"Subchronic phencyclidine causes adaptive changes in GABAergic transmission and LTP threshold in the hippocampus","volume":"100","author":"Nomura","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2015.10.044_bib0260","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1523\/JNEUROSCI.19-07-02693.1999","article-title":"Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices","volume":"19","author":"Alkondon","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2015.10.044_bib0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1385\/MN:26:2-3:203","article-title":"Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications","volume":"26","author":"Yan","year":"2002","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1121325","article-title":"Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits","volume":"311","author":"Szabadics","year":"2006","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bbr.2015.10.044_bib0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/mol.111.076141","article-title":"The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses","volume":"81","author":"Yuen","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbr.2015.10.044_bib0280","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/S1461145712001332","article-title":"Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats","volume":"16","author":"Luoni","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432815302564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432815302564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T08:12:43Z","timestamp":1748679163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432815302564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":56,"alternative-id":["S0166432815302564"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2015.10.044","relation":{},"ISSN":["0166-4328"],"issn-type":[{"type":"print","value":"0166-4328"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2015.10.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}